|Day Low/High||15.85 / 17.06|
|52 Wk Low/High||11.00 / 23.53|
Gregg Greenberg breaks down today's market action with guests Michael Gregory, portfolio manager for the Highland Capital Long/Short Fund, Ken Shreve, TheStreet's Market Movers portfolio manager and Ed Ferko, senior manager for Vanguard's College Savings Plan Group.
Analyst lowers Boston Scientific but upgrades 4 other medical device makers to 'Outperform'
Thoratec says 3Q profit surges on success of heart pump; guidance boosts shares
There defensive names are companies whose products sell no matter how bad the economy is.
ISTA Pharmaceuticals plunged following an FDA rejection, helping keep health stocks flat.
Aspreva and CryoLife advance after projecting strong first-quarter results.
Myriad Genetics rises on better-than-expected second-quarter results.
Thoratec falls as a weak outlook overshadows better-than-expected earnings.
The company indicates Destination Therapy implants aren't up to snuff for the fourth quarter.
That kind of move is a caution signal. Plus, a chart review of Microsoft, Barrick Gold and more.
A NASD complaint alleges Peter Kellogg made fraudulent trades in medical-equipment company Thoratec.
As the larger indices bounce within channels, many stocks aren't moving with the market.
Good traders don't try to outsmart the market. Also, a look at Thoratec, United Online and others.
Question your approach, but you might already have the correct plan of action.
The Chartman explains how the stock could go to $15. Plus, Expedia, Barrick Gold and more.
More small to midsize firms are announcing shortfalls, but overall, the percentage fell.
Time will tell if a replacement heart is as good a business as it is a story.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.